Muscarinic acetylcholine receptors as therapeutic targets for obesity

Expert Opinion on Therapeutic Targets

Volumn 12, Issue 9, 2008, Pages 1167-1175

  Maresca, Alfonso ^a   Supuran, Claudiu T ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Acetylcholine; Darifenacin; M3 muscarinic receptor; M3 receptor deficient mice; Solifenacin

Indexed keywords

1 (6 AMINOPYRIDYN 2 YLMETHYL)PIPERIDINAMIDE; 4 (2 AMINOETHYL)PIPERIDINAMIDE; ATROPINE; DARIFENACIN; INSULIN; LEPTIN; MUSCARINIC AGENT; MUSCARINIC M3 RECEPTOR; MUSCARINIC M3 RECEPTOR ANTAGONIST; MUSCARINIC RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; OXYBUTYNIN; PILOCARPINE; PIPERIDINE DERIVATIVE; SOLIFENACIN; TOLTERODINE;

BINDING AFFINITY; BLURRED VISION; CONSTIPATION; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; ENERGY BALANCE; FOOD INTAKE; GLUCOSE HOMEOSTASIS; GLUCOSE TOLERANCE; HUMAN; HYPOTHALAMUS; INSULIN SENSITIVITY; NONHUMAN; OBESITY; RECEPTOR AFFINITY; REVIEW; XEROSTOMIA;

ANIMALS; ANTI-OBESITY AGENTS; MICE; MOLECULAR STRUCTURE; MUSCARINIC ANTAGONISTS; OBESITY; RECEPTORS, MUSCARINIC;

EID: 51549110137     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.12.9.1167     Document Type: Review

References (24)

1. 3 muscarinic acetylcholine receptor deficiency. Cell Metab 2006;4:363-75
2. Wess J. Molecular biology of muscarinic acetylcholine receptors. Crit Rev Neurobiol 1996;10:69-99
3. Wess J, Eglen RM, Gautam D. Muscarinic acetylcholine receptors. Mutant mice provide new insights for drug development. Nat Rev Drug Discov 2007;6:721-33
4. Caulfield MP, Birdsall NJM; International Union of Pharmacology, XVII. Classification of muscarinic acetylcholine receptors. Pharmacol Rev 1998;50:279-90
5. Volpicelli LA, Levey AI. Muscarinic acetylcholine receptors subtypes in cerebral cortex and hyppocampus. Prog Brain Res 2004;145:59-66
6. Abrams P, Andersson KE, Buccafusco JJ, et al. Muscarinic receptors: their distribution and function in body systems, and the implication for treating overactive bladder. Br J Pharmacol 2006;148:565-78
7. 3 muscarinic acetylcholine receptor are hypophagic and lean. Nature 2001; 410:207-12
8. Flier J, Maratos-Flier E. Obesity and hypothalamus: novel peptides for new pathways. Cell 1998;92:437-40
9. Elmquist JK, Elias CF, Saper CB. From lesions to leptin: hypothalamic control of food intake and body weight. Neuron 1999;22:221-32
10. Schwartz MW, Woods SC, Porte D Jr, et al. Central nervous system control of food intake. Nature 2000;404:661-71
11. Elias CF, Saper CB, Maratos-flier E, et al. Chemically defined projections linking the mediobasal hypothalamus and the lateral hypothalamic area. J Comp Neurol 1998;402:443-59
12. Broberger C, De Lecea L, Sutcliffe JG, et al. Hypocretin/orexin- and melanin-concentrating hormone-expressing cells form distinct populations in the rodent lateral hypothalamus: relationship to the neuro peptide Y and agouti gene-related protein system. J Comp Neurol 1998;402:460-74
13. Bergen HT, Mitzuno TM, Taylor J, et al. Hyperphagia and weight gain after gold-thioglucose: relation to hypothalamic neuropeptide Y and proopiomelanocortin. Endocrinology 1998;139:4483-8
14. Hoffman BB, Taylor P. In: Hardman JG, Limbird JF, Gilman AG. Goodman & Gilman's The pharmacological basis of therapeutics. X edition. New York: McGraw-Hill; 2001
15. Nonogaky K. New insights into sympathetic regulation of glucose and fat metabolism. Diabetologia 2000;43:533-49
16. 3 selective antagonists (Part 1). J Med Chem 2007;50:1571-83
17. Greene J, Kahn S, Savoj H, et al. Chemical function queries for 3D database search. J Chem Inf Comput Sci 1994;34:1297-308
18. Hedge SS. Muscarinic receptors in the bladder: from basic researh to therapeutics. Br J Pharmacol 2006;147:S80-7
19. Kurogi Y, Guner OF. Pharmacophore modeling and three-dimensional database searching for drug design using catalyst. Curr Med Chem 2001;8:1035-55
20. Peretto I, Fossati C, Giardina GAM, et al. Discovery of diaryl imidazolidin-2-one derivates, a novel class of muscarinic M3 selective antagonists (Part 2). J Med Chem 2007;50:1693-7
21. Mitsuya M, Kobayashi K, Kawakami K, et al. A potent, long active (2R)-2[(1R)-3,3-difluorocyclopentyl]-2-hydroxy-2-phenylacetamide: novel muscarinic M(3) receptor antagonist with high selectivity for M(3) over M(2) receptors. J Med Chem 2000;43:5017-29
22. 3 receptor antagonists with (2R)-2[(IR)-3,3-difluorocyclopentyl]-2-hydroxy-2-phenylacetamide structures. Part 2. Bioorg Med Chem Lett 2003;13:2167-72
23. 3 Selectivity. J Med Chem 2006;49:5653-63
24. Steers DW. Darifenacin: pharmacology and clinical usage. Urol Clin N Am 2006;475-82